|
ZRANB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64201985342061E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.69764202695433E-12 |
| Normal-vs-Stage2 |
1.9110999449623E-09 |
| Normal-vs-Stage3 |
7.7715611723761E-16 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
2.915800E-01 |
| Stage1-vs-Stage3 |
6.244000E-02 |
| Stage1-vs-Stage4 |
6.479300E-03 |
| Stage2-vs-Stage3 |
2.033800E-02 |
| Stage2-vs-Stage4 |
7.415900E-03 |
| Stage3-vs-Stage4 |
4.074400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.99440505513849E-15 |
| Normal-vs-AfricanAmerican |
2.36580000001485E-06 |
| Normal-vs-Asian |
5.77227154963111E-12 |
| Caucasian-vs-AfricanAmerican |
7.996100E-02 |
| Caucasian-vs-Asian |
9.873000E-01 |
| AfricanAmerican-vs-Asian |
1.746410E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.65145674912992E-12 |
| Male-vs-Female |
5.870200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.90718576884319E-14 |
| Normal-vs-Age(41-60Yrs) |
1.67643676718399E-14 |
| Normal-vs-Age(61-80Yrs) |
1.99840144432528E-14 |
| Normal-vs-Age(81-100Yrs) |
3.616200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.911600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.880200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.454000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.354800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.453000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.799800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.655000E-03 |
| Classical-VS-Follicular |
1.308040E-01 |
| Classical-VS-Other |
5.228600E-01 |
| Classical-VS-Normal |
1.47437617670221E-13 |
| Tall-VS-Follicular |
4.592400E-04 |
| Tall-VS-Other |
5.063800E-01 |
| Tall-VS-Normal |
1.62492241884138E-12 |
| Follicular-VS-Other |
3.147800E-01 |
| Follicular-VS-Normal |
1.19629861572434E-11 |
| Other-VS-Normal |
1.584290E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62470037423645E-12 |
| N0-vs-N1 |
7.998200E-03 |
|
|
